Revenue decline in Q1 2026 (-5% YoY) is a near-term headwind, but FY26 guidance for 2-4% growth and 6-10% adjusted EBITDA growth suggests management expects a recovery. The debt refinancing and manufacturing consolidation provide tangible cost savings. Watch Q2 2026 results for confirmation of the growth trajectory and monitor execution on Project Viking's $3M EBITDA target for 2027.
Price Chart
Executive Summary
Harvard Bioscience filed an 8-K with an investor presentation providing FY26 guidance of 2-4% revenue growth and 6-10% adjusted EBITDA growth, alongside Q1 2026 results showing a 5% YoY revenue decline to $20.8M. The presentation highlights a $40M debt refinancing with BroadOak that reduced annual debt service by $3M, and a manufacturing consolidation (Project Viking) expected to deliver $3-4M in annual EBITDA savings by 2027-2028.
Key Facts
- Q1 2026 revenue declined 5% YoY to $20.8M from $21.8M
- FY26 revenue guidance: 2-4% growth; FY25 revenue was $87M
- FY26 adjusted EBITDA growth guidance: 6-10%; FY25 adjusted EBITDA was $8M
- FY26 adjusted gross margin guidance: 58-60%; FY25 was 58%
- Q2 2026 revenue guidance: $20.5M-$22.5M
- Q2 2026 adjusted EBITDA guidance: $1M-$2M
- Debt refinancing: $40M deal with BroadOak, extended maturity to 2029, $3M annual cash savings
- Project Viking: manufacturing consolidation expected to deliver ~$3M EBITDA improvement in 2027 and ~$4M from 2028
- 54% recurring revenue in FY25 with path to 60%+
- Net debt of $32.9M as of March 31, 2026
Financial Impact
Q1 2026 revenue declined $1M YoY (-5%); FY26 guided 2-4% growth on $87M base implies $1.7M-$3.5M revenue increase; debt refinancing saves $3M/year in cash; Project Viking adds $3-4M EBITDA by 2028
Risk Factors
- Q1 2026 revenue decline of 5% YoY driven by Americas (-9%) and APAC (-9%) weakness
- NIH funding delays impacting academic and government sales in the Americas
- High debt load ($36.2M gross debt) with 12.8% interest rate and 10% exit fee on refinancing
- Execution risk on manufacturing consolidation and achieving projected cost savings
- Reverse stock split and S3 filing indicate potential capital concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003271 |
| Document: f8k_051226.htm | 0001171843-26-003271 |
| Document: 0001171843-26-003271-index-headers.html | 0001171843-26-003271 |
| Document: 0001171843-26-003271-index.html | 0001171843-26-003271 |
| Document: 0001171843-26-003271.txt | 0001171843-26-003271 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | SC 13G/A | $7.92 | awaiting T+60 | — | $8.32 (+5.05%) |
Aug 11, 2026 10w ago | 8-K | $6.13 | awaiting T+60 | — | $8.32 (+35.73%) |
Aug 11, 2026 10w ago | 8-K | $6.13 | awaiting T+60 | — | $8.32 (+35.73%) |
Jul 28, 2026 12w ago | Press Release | $5.92 | awaiting T+60 | — | $8.32 (+40.54%) |
Jun 2, 2026 20w ago | 8-K | $6.50 $7.90 | ▲ +21.54% | ▲ +19.04% | $8.32 (+28.00%) |
May 12, 2026 23w ago | 8-K | $5.41 $6.19 | ▲ +14.42% | ▲ +10.03% | $8.32 (+53.79%) |
May 12, 2026 23w ago | 8-K | $5.41 $6.19 | ▼ −14.42% | ▼ −10.03% | $8.32 (−53.79%) |
May 12, 2026 23w ago | Press Release | $5.41 $6.19 | ▲ +14.42% | ▲ +10.03% | $8.32 (+53.79%) |
Mar 16, 2026 32w ago | Insider Cluster | $5.01 $6.01 | ▲ +19.96% | ▲ +9.48% | $8.32 (+66.07%) |
Mar 16, 2026 32w ago | Insider Cluster | $5.01 $6.01 | ▲ +19.96% | ▲ +9.48% | $8.32 (+66.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers